Revenues for the quarter ended Sept. 30 totaled $20.4 million, compared to $14.1 million during the same quarter last year. The company attributed the increase primarily to a growth in product sales, including sales of reagents and disposables.
R&D spending during the quarter increased slightly to $4.8 million, compared to $4 million during the third quarter last year.
Cepheid reported a net loss of $3.3 million during the third quarter, compared with a net loss of $2.9 million during the same quarter last year.
As of Sept. 30, Cepheid had $10 million in cash and cash equivalents, and $30.2 million in marketable securities.